Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer (MBC). In this educational program, these experts discuss current treatment options for HR+/HER2– MBC across the continuum from endocrine-sensitive to endocrine-resistant disease. Topics include pivotal data from clinical trials in the first-line and recurrent settings, biomarker testing, sequencing considerations, and how emerging data may further impact current treatment paradigms.
This educational activity is an archive of the live symposium held on March 5, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, oncology nurses, advanced practice professionals, pathologists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data supporting novel therapies and combinations for HR+/HER2– metastatic breast cancer (MBC)
- Apply practical strategies for tailoring first-line and subsequent therapy choices based on patient, disease, and biomarker characteristics in HR+/HER2– MBC
- Implement streamlined strategies for monitoring and mitigating class-specific toxicities of targeted therapies in HR+/HER2– MBC
Kevin Kalinsky, MD, MS
Professor, Department of Hematology and Medical
Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bicycle Therapeutics, bioTheranostics, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead, Jazz Pharmaceuticals, Menarini Silicon Biosystems, Merck, Mersana, Myovant Sciences, Novartis, Pfizer, ProteinQure, Puma Biotechnology, RayzeBio, Regor, Relay Therapeutics, Seattle Genetics
Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Agendia, AstraZeneca, Bria-Cell, Celcuity, Daiichi Sankyo, Genentech/Roche, Gilead, Lilly, Merck, Myriad, Novartis, Pfizer, Puma, Sanofi; Ownership Interests in Privately Held Companies: Celcuity
Kelly Elizabeth McCann, MD, PhD
Assistant Clinical Professor
David Geffen School of Medicine
Jonsson Comprehensive Cancer Center
UCLA Hematology and Oncology
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, BioNTech, Biotheranostics, Biovica, Daiichi Sankyo, Eli Lilly, Halda Therapeutics OpCo, Novartis, Pfizer, Puma Biotech, Sermonix, Stemline, Summit Therapeutics, TerSera; Speakers Bureau: Eli Lilly; Grant/Research Funding: Ambrx, AstraZeneca, BriaCell, Duality Biologics, Eli Lilly, G1 Therapeutics, Gilead, H3 Biomedicine, Immunomedics, MacroGenics, Marengo Therapeutics, Merck, Novartis, Olema, Pfizer, Puma Biotech, Roche/Genentech, Sanofi, Stemline, Zymeworks
Sara Nunnery, MD, MSCI
Director of Breast Cancer Research
Tennessee Oncology
Nashville, TN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Arvinas, Daiichi Sankyo, Gilead, Menarini Stemline, Merck, Novartis, Pfizer; Grant/Research Funding: AstraZeneca, BioNTech, DualityBio, Genentech, Menarini Stemline, Merck, Olema, Puma Biotechnology, Relay Therapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.